Physician profile
Malena C Sample
NPI 1053323659
$1,870.15
in general payments reported to CMS, 2019-2025
25 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $137 · 2021: $166 · 2022: $279 · 2023: $227 · 2024: $245 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $610.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $558.65 | 2019-2023 | Orilissa |
| Amgen INC. | $185.43 | 2019-2025 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $157.41 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $155.18 | 2023-2025 | Veozah |
| Organon LLC | $97.91 | 2022-2023 | Nexplanon |
| Therapeuticsmd, INC. | $72.76 | 2019-2022 | |
| Hologic Sales and Service, LLC | $67.00 | 2019-2024 | Aptima |
| Myovant Sciences INC. | $63.92 | 2022 | |
| Coopersurgical, INC. | $61.99 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $61.36 | 2019-2020 | |
| Pfizer INC. | $53.54 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $48.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.34 | 2019-2021 | |
| Covidien LP | $30.99 | 2019-2020 | |
| Channel Medsystems, INC. | $26.66 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $24.67 | 2022 | |
| Avion Pharmaceuticals | $21.12 | 2022 | |
| Scynexis, INC. | $20.63 | 2022 | |
| Biogen, INC. | $19.90 | 2024 | Zurzuvae |
| Agile Therapeutics, INC. | $17.81 | 2023 | Twirla |
| Vertical Pharmaceuticals, LLC | $17.64 | 2019 | |
| Minerva Surgical, INC | $16.54 | 2024 | |
| Duchesnay USA Incorporated | $16.19 | 2019 | |
| Lupin INC. | $14.34 | 2019 | |
| Mission Pharmacal Company | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malena Sample listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.